enGene Therapeutics Inc. expected to post a loss of 43 cents a share - Earnings Preview

enGene Therapeutics

07/09/2026 12:01

enGene Therapeutics Inc. ENGN.OQ ENGN.O is expected to  show no change in quarterly revenue when it reports  results on September 9 (estimated) for the period ending July 31 2026

​LSEG's mean analyst estimate for enGene Therapeutics Inc. is for a loss of 43 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for enGene Therapeutics Inc. is $4.00, about 119.8% above its last closing price of $1.82
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Apr. 30 2026
-0.47
-0.47
-0.43
Beat
8.5
Jan. 31 2026
-0.57
-0.56
-0.44
Beat
21.4
Oct. 31 2025
-0.57
-0.57
-0.73
Missed
-28.5​
Jul. 31 2025
-0.51
-0.50
-0.57
Missed
-13.7
​​Apr. 30 2025
-0.53
-0.50
-0.51
Missed
-2.4
Jan. 31 2025
-0.36
-0.37
-0.48
Missed
-29.3​
Oct. 31 2024
-0.39
-0.38
-0.34
Beat
10
Jul. 31 2024
-0.43
-0.37
-0.32
Beat
14.7
This summary was machine generated September 7 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)